

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*

WHO Technical Report Series

872

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Forty-sixth Report



World Health Organization

Geneva 1998

WHO Library Cataloguing in Publication Data

WHO Expert Committee on Biological Standardization (1995 : Geneva, Switzerland)
WHO Expert Committee on Biological Standardization : forty-sixth report.

(WHO technical report series ; 872)

1. Biological products — standards I. Title II. Series

ISBN 92 4 120872 4
ISSN 0512-3054

(NLM Classification: QW 800)

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

© World Health Organization 1998

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

**Typeset in Hong Kong
Printed in Spain**

97/11379 – Best Set/Fotojoe – 7500

Contents

Introduction	1
General	1
Development and distribution of International Biological Standards and Reference Reagents	1
Need for interim standards with an official status conferred by WHO	4
Cytokines	4
Standardization and priorities for action in the field of diagnostics	6
Advice to United Nations agencies on the quality of vaccines	7
Yellow fever vaccine	8
Reverse-transcriptase activity associated with avian cells	8
Glossary of terms	8
Review of biological standardization	9
Committee meetings	10
Requirements for biological substances	10
Requirements for cell substrates used for biologicals production	10
Requirements for oral poliomyelitis vaccine	11
Requirements for snake antivenoms	11
Requirements for thromboplastins and plasma used to control oral anticoagulant therapy	12
Requirements for yellow fever vaccine	12
General requirements for the sterility of biological substances (amendment, 1995)	13
Guidelines for minimizing the risk of transmitting agents causing bovine spongiform encephalopathy	13
Guidelines for the production and control of synthetic peptide vaccines	13
Summary protocol for the batch release of virus vaccines	14
Antibiotics	14
Gentamicin	14
Antibodies	15
Anti-borrelia serum	15
Anti-cytomegalovirus immunoglobulin and serum	15
Anti-hepatitis B core antigen serum	16
Anti-hepatitis E virus serum	16
Anti-measles serum	16
Anti-mumps serum	17
Anti-parvovirus B19 IgG serum	17
Anti-pertussis serum	17
Anti-rubella immunoglobulin and serum	18
Anti-streptolysin O serum	18
Anti-toxoplasma serum	18
Anti-varicella zoster IgG serum	19
Thyroid-stimulating antibody	19

Antigens and related substances	19
Pertussis vaccine (whole cell)	19
Poliomyelitis vaccine (inactivated)	20
Live attenuated poliovirus	20
Blood products and related substances	21
Factors II, VII, IX and X in plasma	21
Factor IXa	21
International working standards in blood coagulation	21
Haemiglobincyanide	22
Mannan-binding protein	22
Plasminogen-activator inhibitor 1	23
Protein S in plasma	23
Recombinant ferritin	23
Thromboplastin	24
Thromboplastin, rabbit, plain	24
Tissue factor pathway inhibitor	24
Tissue plasminogen activator in plasma	25
Whole blood folate	25
Cytokines	25
Interferon gamma, human	25
Interleukin-8	26
Insulin-like growth factor-binding protein 3	26
Endocrinological and related substances	26
Follicle-stimulating hormone	26
Osteopietin	27
Toxins	28
Endotoxin	28
Annex 1	
Laboratories approved by WHO for the production of yellow fever vaccine	29
Annex 2	
Requirements for yellow fever vaccine (Requirements for Biological Substances No. 3, revised 1995)	30
Annex 3	
General requirements for the sterility of biological substances (Requirements for Biological Substances No. 6, revised 1973, amendment 1995)	69
Annex 4	
Summary protocol for the routine batch release of virus vaccines	75
Annex 5	
Biological substances: International Standards and Reference Reagents	80

Annex 6	
Requirements for Biological Substances and other sets of recommendations	83
Annex 7	
Corrigenda: reference materials for anti-interferon alfa and beta sera; interferon gamma, recombinant human; and mumps vaccine (live)	90

WHO Expert Committee on Biological Standardization

Geneva, 17–24 October 1995

Members

- Dr D.H. Calam, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Rapporteur*)
- Dr S.G. Drozdov, Director, Institute of Poliomyelitis and Viral Encephalitis, Moscow, Russian Federation
- Dr I.D. Gust, Research and Development Director, CSL Ltd, Parkville, Victoria, Australia
- Dr Z. Khan, Principal Scientific Officer, Quality Control Division, National Institute of Health, Islamabad, Pakistan
- Dr J.G. Kreeftenberg, Bureau for International Cooperation, National Institute for Public Health and Environmental Protection, Bilthoven, Netherlands (*Vice-Chairman*)
- Dr J.M.Y. Niquir, Director, National Blood Bank, al-Ashrafieh, Amman, Jordan
- Dr F.A. Ofosu, Department of Pathology, McMaster University, Hamilton, Ontario, Canada
- Dr J.C. Petricciani, Vice-President, Genetics Institute, Cambridge, MA, USA (*Chairman*)
- Mr Zhou Hai-jun, Director, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China

Representatives of other organizations

Council of Europe

- Mr J.-M. Spieser, Principal Scientific Officer, Biological Standardization Department, European Pharmacopoeia Commission, Council of Europe, Strasbourg, France

International Association of Biological Standardization

- Professor F. Horaud, Pasteur Institute, Paris, France

International Federation of Clinical Chemistry

- Dr A. Deom, Liaison Officer with WHO, Responsible Officer, Quality Assurance, Cantonal Hospital, Geneva, Switzerland

International Federation of Pharmaceutical Manufacturers Associations

- Dr M. Duchêne, Director, Quality Control and Regulatory Affairs, SmithKline Beecham Biologicals, Rixensart, Belgium
- Dr B. Montagnon, Head, Registration, Pasteur Mérieux Sera and Vaccines, Marcy l'Etoile, France

International Society on Thrombosis and Haemostasis

- Dr T.W. Barrowcliffe, National Institute for Biological Standards and Control, Potters Bar, Herts., England

Secretariat

- Dr A.F. Bristow, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)
- Dr V. Grachev, Scientist, Biologicals, WHO, Geneva, Switzerland
- Dr E. Griffiths, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)

- Dr G.A. Hansen, Statens Seruminstitut, Copenhagen, Denmark (*Temporary Adviser*)
- Dr M.C. Hardegree, Director, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA (*Temporary Adviser*)
- Dr J.E. Idänpään-Heikkilä, Director, Division of Drug Management and Policies, WHO, Geneva, Switzerland
- Dr A. Padilla, Scientist, Biologicals, WHO, Geneva, Switzerland
- Dr G. Siegl, Institute for Microbiology and Immunology, St Gallen, Switzerland (*Temporary Adviser*)
- Dr W.G. van Aken, Medical Director, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Temporary Adviser*)
- Dr K. Zoon, Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA (*Temporary Adviser*)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30682

